Relay Therapeutics CFO Sells $27,000 in Stock

Catinazzo's sale represents a 0.83% decrease in his position

Apr. 12, 2026 at 9:34am

Got story updates? Submit your updates here. ›

A high-contrast, cinematic close-up photograph of intricate banking and computing machinery, representing the unseen technological backbone of the pharmaceutical industry.A behind-the-scenes look at the complex financial infrastructure powering Relay Therapeutics' drug development efforts.Cambridge Today

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 1,800 shares of the company's stock on April 9th for a total value of $27,000. Following the sale, Catinazzo directly owned 213,867 shares in the company, valued at $3,208,005.

Why it matters

This transaction provides insight into the financial activities and holdings of Relay Therapeutics' leadership team. Stock sales by executives can sometimes signal changes in a company's outlook or strategy, though the sale here appears to be a routine transaction under a pre-arranged trading plan.

The details

Catinazzo's stock sale represented a 0.83% decrease in his position. The shares were sold at an average price of $15.00. Relay Therapeutics is a clinical-stage biotech company focused on developing precision therapies for oncology, leveraging computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates.

  • The stock sale occurred on Thursday, April 9th, 2026.

The players

Thomas Catinazzo

The chief financial officer of Relay Therapeutics, Inc.

Relay Therapeutics, Inc.

A clinical-stage biotechnology company focused on developing precision therapies for oncology.

Got photos? Submit your photos here. ›

The takeaway

This stock sale by Relay Therapeutics' CFO appears to be a routine transaction and does not necessarily signal any broader changes at the company. Investors will likely continue to monitor Relay's progress in developing its pipeline of oncology therapies.